SCHEDULE: StemPoint Capital Discloses 9.9% Stake in Sensei Biotherapeutics
Schedule 13G Filing
StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross have jointly filed a Schedule 13G, reporting beneficial ownership of 132,873 shares, representing 9.9% of Sensei Biotherapeutics, Inc. common stock.
Summary
- StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating their beneficial ownership of Sensei Biotherapeutics, Inc. common stock.
- The Reporting Persons collectively beneficially own 132,873 shares of Sensei Biotherapeutics, Inc. common stock.
- This ownership stake represents 9.9% of the total outstanding shares of common stock.
- The calculation is based on 1,340,281 shares outstanding as of March 23, 2026, as reported in Sensei Biotherapeutics' Form 10-K for the annual period ended December 31, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports an existing ownership stake without new strategic information or financial performance data.
Positives
- Significant ownership stake of 9.9% in Sensei Biotherapeutics, Inc. by StemPoint Capital and Michelle Ross, indicating investor confidence or strategic interest.
Future Outlook
This filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes by institutional investors or significant shareholders. A 9.9% stake is a notable position, suggesting a substantial investment in Sensei Biotherapeutics, Inc. by StemPoint Capital and Michelle Ross.
Stakeholder Impact
- Shareholders: The filing provides transparency regarding a significant ownership stake, which may influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Annual period ended for Sensei Biotherapeutics' Form 10-K. |
| 2026-03-23 | Date as of which outstanding shares of Common Stock were reported. |
| 2026-03-30 | Date Sensei Biotherapeutics' Form 10-K for the annual period ended December 31, 2025 was filed with the SEC. |
| 2026-03-31 | Date of Event Which Requires Filing of this Statement (Schedule 13G). |
| 2026-05-15 | Date of signatures on the Schedule 13G and Joint Filing Agreement. |
Keywords
Schedule 13G, Sensei Biotherapeutics, StemPoint Capital, Michelle Ross, Beneficial Ownership, SEC Filing, Common Stock, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.